Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDORA: Pantoprazole and Docetaxel in mCRPC
NCT01748500Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jan 2013
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pantoprazole in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University Health Network. Primary endpoint: Prostate-Specific Antigen Response at 20 months. Started Jan 2013; status: completed.
02
Drugs
pantoprazole
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01748500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748500.